Generated by AI
BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines for neuroscience and immuno-oncology using artificial intelligence and data-driven drug discovery. Its current portfolio includes IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, as well as investigational programs built around BXCL501 and other proprietary candidates. The company’s neuroscience work addresses conditions such as agitation in dementia and major depressive disorder, while its immuno-oncology efforts are centered on oral immune-activating therapies for aggressive cancers through its subsidiary, OnkosXcel Therapeutics. Headquartered in New Haven, Connecticut, BioXcel Therapeutics operates as a commercial-stage specialty biotechnology company with a focus on advancing targeted treatment options in areas with significant unmet medical need.
Website555 Long Wharf Drive
New Haven, CT, 06511
United States
The latest articles about BTAI.
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Limited (NYSE:TEVA), agreed to serve as the stalking-horse bidder for substantially all assets of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) and certain affiliates through a court-supervised Chapter 11 auction. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is the parent of the bidder and guarantor of the milestone-payment obligations. The […]
Summary of Sep 4's posts. Generated by AI.
Summary of Mar 9's posts. Generated by AI.
Summary of Jun 30's posts. Generated by AI.
Summary of Sep 4's posts. Generated by AI.
Investors talking about BTAI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.